<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421408</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR053701</org_study_id>
    <secondary_id>R01AR053701</secondary_id>
    <secondary_id>1R01AR053701-01A1</secondary_id>
    <nct_id>NCT00421408</nct_id>
  </id_info>
  <brief_title>The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women</brief_title>
  <official_title>Impact of a Protein Supplement on Bone Mass in Older Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women and men consuming a low protein diet may be at risk for bone loss. The purpose of this
      study is to determine whether a daily protein supplement will improve bone health among
      healthy older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dietary protein plays an important role in maintaining balanced calcium levels in the body.
      Protein's impact on skeletal health remains unclear. It is well accepted that increasing
      dietary protein results in greater excretion of calcium through urine. The excreted calcium
      is thought to come in part from bone, which would suggest a negative effect on bone health.
      However, recent studies have found that higher protein intake is, in fact, associated with
      higher bone mineral density and lower rates of bone loss. The purpose of this study is to
      determine if a daily protein supplement will improve bone health and hormonal measures of
      bone metabolism among healthy older men and women who consume low-to-normal levels of dietary
      protein.

      This study will last 18 months. For the duration of the study, participants will be randomly
      assigned to receive either a 40-gram protein supplement or placebo daily. There will be a
      total of nine study visits that will occur at screening, study entry, Month 1.5, and every
      three months thereafter. Dietary records, nutritional counseling, glucose finger stick tests,
      and questionnaires related to falls, physical activity, habits, and study satisfaction will
      occur at all study visits. Blood and urine collection, functional testing, and bone mineral
      density (BMD) testing will occur at selected visits. At Months 0 and 18, half of the
      participants will undergo a quantitative computed tomography (CT) scan to determine bone
      mineral density.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline</measure>
    <time_frame>Measured at baseline and 18 months</time_frame>
    <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) Compared to Baseline</measure>
    <time_frame>Measured at baseline and 18 months</time_frame>
    <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at Baseline</measure>
    <time_frame>Measured at 0 months</time_frame>
    <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 9 Months</measure>
    <time_frame>Measured at 9 months</time_frame>
    <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 18 Months</measure>
    <time_frame>Measured at 18 months</time_frame>
    <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at Baseline</measure>
    <time_frame>Measured at 0 months</time_frame>
    <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at 18 Months</measure>
    <time_frame>Measured at 18 months</time_frame>
    <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Bone Resorption</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Protein powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a protein supplement daily (40 g whey protein supplement).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo carbohydrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo supplement daily (40 g maltodextrin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey protein supplement</intervention_name>
    <description>40-g whey protein supplement daily for 18 months</description>
    <arm_group_label>Protein powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplement daily for 18 months</description>
    <arm_group_label>Placebo carbohydrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to travel to one of the study sites

          -  Women age 60 years or greater, men age 70 years or greater

          -  Dietary protein intake level between 0.6 g/kg and 1.0 g/kg at baseline

        Exclusion Criteria:

          -  Active Paget's disease

          -  Primary hyperparathyroidism or unexplained hypercalcemia

          -  Untreated hyperthyroidism or hyperthyroidism that has resulted from medical treatment

          -  Diabetes mellitus type 1

          -  Cancer diagnosis for solid malignancies (e.g., cancer of the colon, breast,prostate,
             lungs, lymphocytes) within the 18 months prior to study entry

          -  Long-term use of chemotherapeutic drugs, aromatase inhibitors, or tamoxifen

          -  Active treatment for leukemia or multiple myeloma

          -  Active inflammatory bowel disease

          -  Life expectancy of less than 2 years

          -  Current and ongoing use of methotrexate, phenytoin, phenobarbital, or inhaled
             corticosteroids at a dose of greater than 800 mcg/day

          -  Use of raloxifene, estrogen, androgen, progesterone, soy isoflavones, oral
             glucocorticoids, or herbal supplements with estrogenic activity OR a change in dosage
             of thyroid medications within the 1 year prior to study entry if unwilling to avoid
             such agents during the duration of the study

          -  Current use of antiresorptive agents (e.g., calcitonin or bisphosphonates). More
             information about this criterion can be found in the protocol.

          -  serum creatinine greater than 1.2 mg/dl

          -  History of chronic liver disease or evidence of liver disease at screening

          -  Bilateral hip replacement

          -  women who have a bone mineral density T-score &lt; -2.5 at either the hip or spine unless
             they have decided to decline treatment with conventional anti-osteoporotic medications

          -  Body mass index (BMI) greater than 32 or less than 19

          -  Use of proton-pump inhibitors taken twice daily

          -  Fasting glucose level greater than 110 mg/dl

          -  Serum albumin level less than 3.0 mg/dl

          -  Kidney stones or history of kidney stones within the 3 years prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl L. Insogna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Newton KM, LaCroix AZ, Levy L, Li SS, Qu P, Potter JD, Lampe JW. Soy protein and bone mineral density in older men and women: a randomized trial. Maturitas. 2006 Oct 20;55(3):270-7. Epub 2006 May 26.</citation>
    <PMID>16730418</PMID>
  </reference>
  <reference>
    <citation>Uenishi K, Ishida H, Toba Y, Aoe S, Itabashi A, Takada Y. Milk basic protein increases bone mineral density and improves bone metabolism in healthy young women. Osteoporos Int. 2007 Mar;18(3):385-90. Epub 2006 Oct 18.</citation>
    <PMID>17048062</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <results_first_submitted>April 30, 2013</results_first_submitted>
  <results_first_submitted_qc>August 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2013</results_first_posted>
  <last_update_submitted>August 26, 2013</last_update_submitted>
  <last_update_submitted_qc>August 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Karl Insogna</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Dietary protein</keyword>
  <keyword>Calcium</keyword>
  <keyword>Parathyroid hormone</keyword>
  <keyword>Bone markers</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>IGF-1</keyword>
  <keyword>Urine Calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Resorption</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in June 2007 and the last participant was screened in October 2010. Subjects were recruited to the Yale Center for Clinical Investigation in New Haven, CT or the University of Connecticut Health Center in Farmington, CT.</recruitment_details>
      <pre_assignment_details>Subjects were randomized 1 month after screening if they were found eligible after screening. Between screening and randomization their calcium and vitamin D intake was stabilized for baseline measurements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
          <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
        </group>
        <group group_id="P2">
          <title>Protein Powder 40 g Daily for 18 Months</title>
          <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discountinued from treatment/ f/u cont.</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy older men and women with no known disorders that affect mineral metabolism and not taking drugs that alter skeletal metabolism.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
          <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
        </group>
        <group group_id="B2">
          <title>Protein Powder 40 g Daily for 18 Months</title>
          <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="6.4"/>
                    <measurement group_id="B2" value="69.9" spread="6.1"/>
                    <measurement group_id="B3" value="70.2" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline</title>
        <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
        <time_frame>Measured at baseline and 18 months</time_frame>
        <population>Only participants with data at the baseline and 18 month timeframe were used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
            <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Protein Powder 40 g Daily for 18 Months</title>
            <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline</title>
          <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
          <population>Only participants with data at the baseline and 18 month timeframe were used in the analysis.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.38"/>
                    <measurement group_id="O2" value="0.51" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) Compared to Baseline</title>
        <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
        <time_frame>Measured at baseline and 18 months</time_frame>
        <population>Only participants with data at the baseline and 18 month timeframe were used in the analysis. Only half of the study partipants were randomized to receive Quantitative Computed Tomography testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
            <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Protein Powder 40 g Daily for 18 Months</title>
            <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) Compared to Baseline</title>
          <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
          <population>Only participants with data at the baseline and 18 month timeframe were used in the analysis. Only half of the study partipants were randomized to receive Quantitative Computed Tomography testing.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="1.08"/>
                    <measurement group_id="O2" value="-2.64" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at Baseline</title>
        <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
        <time_frame>Measured at 0 months</time_frame>
        <population>All participants were analyzed using the mixed models method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
            <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Protein Powder 40 g Daily for 18 Months</title>
            <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at Baseline</title>
          <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
          <population>All participants were analyzed using the mixed models method.</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="0.01"/>
                    <measurement group_id="O2" value="1.13" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 9 Months</title>
        <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
        <time_frame>Measured at 9 months</time_frame>
        <population>All participants were analyzed using the mixed models method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
            <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Protein Powder 40 g Daily for 18 Months</title>
            <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 9 Months</title>
          <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
          <population>All participants were analyzed using the mixed models method.</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.02"/>
                    <measurement group_id="O2" value="1.12" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 18 Months</title>
        <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
        <time_frame>Measured at 18 months</time_frame>
        <population>All participants were analyzed using the mixed models method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
            <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Protein Powder 40 g Daily for 18 Months</title>
            <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior-posterior Spine Bone Mineral Density Measured by Dual Energy X-ray Absorptiometry (DXA) at 18 Months</title>
          <description>There is no absolute normative range for bone mineral density. Population norms have been established for specific races and men and women for the hip based on data collected by National Health Examination Nutrition Surveys (NHANES) and for the spine based largely on data collected by individual manufacturers. Values within 1 standard deviation of the population mean are generally considered normal. Values below 1 standard deviation from the population mean are generally considered to reflect reduced bone mass.</description>
          <population>All participants were analyzed using the mixed models method.</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.02"/>
                    <measurement group_id="O2" value="1.12" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at Baseline</title>
        <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
        <time_frame>Measured at 0 months</time_frame>
        <population>All participants were analyzed using the mixed models method. For the Quantitative Computed Tomography (QCT) test only half of the participants were randomized to receive it.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
            <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Protein Powder 40 g Daily for 18 Months</title>
            <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at Baseline</title>
          <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
          <population>All participants were analyzed using the mixed models method. For the Quantitative Computed Tomography (QCT) test only half of the participants were randomized to receive it.</population>
          <units>mg/cm^3</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" spread="3.72"/>
                    <measurement group_id="O2" value="103" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at 18 Months</title>
        <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
        <time_frame>Measured at 18 months</time_frame>
        <population>All participants were analyzed using the mixed models method. For the Quantitative Computed Tomography (QCT) test only half of the participants were randomized to receive it.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Carbohydrate 40 g Daily for 18 Months</title>
            <description>Participants will receive a placebo supplement daily (40 g maltodextrin).
Placebo : Placebo supplement daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Protein Powder 40 g Daily for 18 Months</title>
            <description>Participants will receive a protein supplement daily (40 g whey protein supplement).
Whey protein supplement : 40-g whey protein supplement daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Spine Bone Mineral Density Measured by Quantitative Computed Tomography (QCT) at 18 Months</title>
          <description>There is no normative data for quantitative computed tomography it is based on local experience.</description>
          <population>All participants were analyzed using the mixed models method. For the Quantitative Computed Tomography (QCT) test only half of the participants were randomized to receive it.</population>
          <units>mg/cm^3</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" spread="4.07"/>
                    <measurement group_id="O2" value="99.3" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data was collected from July 2007 to May 2012</time_frame>
      <desc>Gastrointestinal adverse events were assessed at times as part of a group of events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Carbohydrate Powder 40 g Daily</title>
        </group>
        <group group_id="E2">
          <title>Protein Powder 40 g Daily</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dramatic drop in blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>surgery for thyroid tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Acute pancreatitits</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>spinal fusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Back surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Hernia surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Hip replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colon resection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Severe nose bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Difficult breathing due to atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Increased duration of heart palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild to moderate gastro-intestinal upset</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="102"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Diagnosed with Barret's esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pain in lower left quadrant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bike accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Car accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Bruise and bleeding post blood draw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Incidental findings on QCT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Burning tongue syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated cholesterol</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculo-skeletal surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Ruptured baker's cyst in knee while walking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Bursa removed from right knee</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Broken bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Mouth cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Basal squamous cells removed from right cheek</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in glomerular filtration rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Bladder tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Attenuating mass in left kidney</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Acute renal failure following cardiac cath procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Asthmatic bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Outpatient hernia surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of this study include the large attrition rate due to the length of the intervention and the difficulty in adhering to 40 grams of protein or placebo powder as a daily supplement.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Karl Insogna</name_or_title>
      <organization>Yale University</organization>
      <phone>203-737-2871</phone>
      <email>Karl.insogna@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

